FDA Beats Otsuka Suit Over Abilify Generics
The U.S. Food and Drug Administration acted permissibly when it approved generic versions of Otsuka Pharmaceutical Co. Ltd.'s antipsychotic Abilify despite remaining market exclusivity for the blockbuster product, a Maryland federal...To view the full article, register now.
Already a subscriber? Click here to view full article